Altris AI is a web-based platform powered by Artificial Intelligence for OCT macula scan interpretation. It is FDA-cleared and CE-certified and is currently working in more than 400 ophthalmic clinics and optometry clinics around the world. Altris AI creates efficiencies in the patient workflow to support ophthalmologists with pathology detection and identification for diagnostic decision-making […]
ECS06 SUBSTITUTION REGENERATIVE THERAPIES FOR LIMBAL, ENDOTHELIAL, AND RETINAL DYSFUNCTION M. V. Tsurkan1,* 1TissueGUARD GmbH, Dresden, Germany TissueGUARD GmbH is a privately-funded biotechnology company dedicated to developing and producing advanced hydrogel materials as medical devices. Our mission is to create innovative biotechnology solutions for tissue and organoid engineering as regenerative therapeutics. At TissueGUARD, we have […]
Cataract surgery is the most commonly performed operation worldwide (Lindstrom, 2015). In the EU alone \>4.3M operations are performed annually(65% of patients are 65+). The leading post-surgical complication is inflammation, causing pain and, if left untreated, visual loss. Extremely high post-cataract surgery inflammation risk mandates a post-operative care routine with all patients requiring corticosteroid eye […]
Avisi Technologies, Inc., an ophthalmic-focused medical device manufacturer, is developing a portfolio of ophthalmic treatments based on a novel metamaterial technology. Avisi’s flagship product, VisiPlate, is a nanotechnology-enabled implant to treat glaucoma. Avisi is developing a portfolio of medical devices for eye care. Commercializing a patented metamaterial platform technology First product is VisiPlate, a minimally […]
ECS18 ENDOART UPDATE, NEW HOPE FOR PATIENTS WHO HAVE FAILED ON HUMAN TISSUE, OR WHO ARE NOT SUITABLE FOR HUMAN TISSUE O. Daphna1* 1EyeYon, Rehovot, Israel EyeYon is currently commercialising EndoArt in a limited market release in the EU, focusing on the most respected KOL’s who are currently generating Real World evidence, demonstrating safety, […]
ECS16 THE CORNEAT ESHUNT, CORNEAT VISION’S REVOLUTIONARY GLAUCOMA DRAINAGE DEVICE: EXTENDING MINIMALLY INVASIVE SURGERY TO SEVERE AND REFRACTORY PATIENTS G. Litvin1,* 1CorNeat Vision, Raanana, Israel CorNeat Vision has developed a number of medical devices, first and foremost the CorNeat eShunt, a revolutionary glaucoma drainage device, that provides, for the first time, a long-lasting, minimally invasive […]
ECS13 DESIGN, EX SITU, AND IN VIVO RESULTS OF THE JELLISEE ACCOMMODATING IOL J. Schallhorn1,* 1University of California, San Francisco, San Francisco, United States A sufficiently effective accommodating intraocular lens (IOL) to replace a cataractous or dysfunctional lens is not currently available, despite decades of development efforts. Using known biomechanical properties of the pediatric […]
ECS12 PRECIZON GO. A NEW CONCEPT OF ENHANCED INTERMEDIATE VISION IOL Ú. Juén1,* 1Ophtec, Groningen, Netherlands The evolution of contemporary lifestyle and standards has led to new demands from our patients. Spectacle independence for intermediate distances and high-quality of vision are in the center of such demands. Addressing these needs, Ophtec has developed an […]
ECS11 LOW ENERGY FEMTOSECOND LASER TREATMENT TO RESTORE ACCOMMODATION CAPACITY TO THE CRYSTALLINE LENS A. Béglé1,* 1KEJAKO, SAINT-ETIENNE, France Purpose To restore crystallin lens capacity of accommodation by changing its mechanical characteristics, using low energy femtosecond laser. Methods We used finite element simulation of the whole eye to understand and model the process of human […]
ECS10 VISUAL SIMULATION TECHNOLOGY FOR MULTIFOCAL CORRECTIONS BEFORE CATARACT OR PRESBYOPIA CORRECTING SURGERY. S. Marcos1,2,* 1CSIC, Madrid, Spain, 2University of Rochester, Rochester, United States UNMET NEED Presbyopia is a non-preventable, gradual, and irreversible eye condition that involves the loss of the ability to focus on near objects. It causes strong visual symptoms in >80% […]
